Czech Republic Pharmaceuticals & Healthcare Report

Published 03 June 2015

  • 109 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Czech Republic Pharmaceuticals & Healthcare Report

BMI View: Pharmaceutical trade within the Czech Republic is expected to rise in the coming years due to a recent pick-up in Eurozone activity driven by Germany. Exports are to see a rise in demand from trading partners based on our expectation of increasing generic penetration throughout Europe and demand for generics in general across emerging markets. We expect imports to be boosted by expanding fiscal expenditure on pharmaceuticals by the Czech healthcare system as positive economic indicators enable the Czech health insurance body (VZP) to boost pharmaceutical expenditure. Investments in Cancer research and diagnosis are also proving successful, bringing closer companies focusing in the lucrative field of oncology.

Headline Expenditure Projections

  • Pharmaceuticals: CZK76.77bn (USD3.43bn) in 2014 to CZK78.83bn (USD3.58bn) in 2015; 2.7% in local currency terms and 4.6% in US dollar terms. Forecasts revised upwards from last quarter.

  • Healthcare: CZK280.80bn (USD12.54bn) in 2014 to CZK284.72bn (USD12.94bn) in 2015; +1.4% in local currency terms and 3.2% in US dollar terms. Forecasts revised upwards from last quarter.

Risk/Reward Inde x

In Q3 2015, results for the Czech Republic on BMI's Risk/Reward Index come in with a Reward score of 62.8 out of 100, a Risk score of 64.1, and an overall score of 63.2 - ranking it as the most attractive market in the Central and Eastern European Region. Drugmakers will face challenges in the Czech pharmaceutical market as a result of pricing pressure, poor access to the market and increasing generic substitution. Additionally, adopted and proposed amendments to healthcare and insurance laws have attracted criticism from the pharmaceutical sector. The Czech pharmaceutical market will nevertheless remain relatively attractive and rewarding due to the regionally high pharmaceutical expenditure per capita compared with its neighbours, an ageing population and a favourable urban-rural distribution.

Key Trends And Developments

    ...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Czech Republic 2011-2019)
17
Healthcare Market Forecast
18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2011-2019)
21
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2011-2019)
21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2011-2019)
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2011-2019)
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2011-2019)
27
Generic Drug Market Forecast
28
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2011-2019)
29
OTC Medicine Market Forecast
30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Czech Republic 2011-2019)
32
Pharmaceutical Trade Forecast
33
Table: Pharmaceutical Trade Data And Forecasts (Czech Republic 2013-2019)
34
Table: Pharmaceutical Trade Data And Forecasts local currency (Czech Republic 2013-2019)
35
Key Risks To BMI's Forecast Scenario
36
Macroeconomic Forecasts
37
Economic Analysis
37
Industry Risk Reward Ratings
40
Central And Eastern Europe Risk/Reward Index
40
Czech Republic - Risk/Reward Index
46
Rewards
46
Risks
46
Market Overview
47
Industry Trends And Developments
48
Epidemiology
48
Healthcare Sector
49
Table: Healthcare Resources (Czech Republic 2009-2014)
51
Table: Healthcare Personnel (Czech Republic 2009-2014)
51
Table: Healthcare Activity (Czech Republic 2009-2014)
52
Healthcare Insurance
52
Healthcare Reforms
53
Hospital Sector
57
Research & Development
57
Clinical Trials
59
Regulatory Development
61
Regulatory Regime
61
Intellectual Property Environment
61
Prescribing Rules
61
Pharmaceutical Advertising
62
Pricing Regime
63
Reimbursement Regime
63
Recent Pricing And Reimbursement Developments
64
Changes To VAT
67
Table: European VAT Rates On Medicines (%)
68
Electronic Tenders
69
Competitive Landscape
70
Pharmaceutical Sector
70
Foreign Industry
71
Pharmaceutical Wholesale
72
Pharmaceutical Retail Sector
72
Table: Retail Pharmacy Market Overview, 2006-2012
72
Company Profile
74
Zentiva (Sanofi)
74
Walmark
78
AstraZeneca
82
Bristol-Myers Squibb
84
Sanofi
86
Novartis
89
GlaxoSmithKline
92
Pfizer
95
Demographic Data
97
Demographic Forecast
97
Table: Population Headline Indicators (Czech Republic 1990-2025)
98
Table: Key Population Ratios (Czech Republic 1990-2025)
98
Table: Urban/Rural Population & Life Expectancy (Czech Republic 1990-2025)
99
Table: Population By Age Group (Czech Republic 1990-2025)
99
Table: Population By Age Group % (Czech Republic 1990-2025)
100
Glossary
102
Methodology
104
Pharmaceutical Expenditure Forecast Model
104
Healthcare Expenditure Forecast Model
104
Notes On Methodology
105
Risk/Reward Index Methodology
106
Index Overview
107
Table: Pharmaceutical Risk/Reward Index Indicators
107
Indicator Weightings
108

The Czech Republic Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech Republic pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Czech Republic, to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Czech pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Czech Republic.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc